Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma

Fig. 6

In vivo effect of b-AP15 in SU-DHL-4 and SU-DHL-2 cells derived mouse xenograft model. Nude mice bearing SU-DHL-4 and SU-DHL-2 cells were treated with either vehicle or b-AP15 (5 mg/kg/d) for 11 days after the average tumor size reached 50mm3. a b-AP15 inhibits tumor growth in vivo. Tumor growth curves were recorded every day in two sets of experiments. Mean ± SD (n = 6). *P < 0.05, **P < 0.01, ***P < 0.0001, versus b-AP15 treatment group. b On day 11 after inoculation, the mice were sacrificed, and the tumor tissues were weighed, imaged and summarized. *P < 0.05, **P < 0.01, ***P < 0.0001, versus control group. c Mice weights were recorded every day after b-AP15 treatment. Mean ± SD (n = 6). d The value of blood test indicators ALT (alanine aminotransferase), AST (aspartate aminotransferase), Cr (creatinine) were shown. Mean ± SD (n = 6). e, f The cell apoptosis and drug specific migration pathways related proteins in tumor tissues were detected by Western blot (SU-DHL-4 control group: #2, #4, #6; b-AP15-treated group: #13, #17, #18; SU-DHL-2 control group: #24, #28, #29; b-AP15-treated group: #32, #36, #37) and/or immunohistochemical (IHC) analysis. All the immunostaining and Western blot were repeated in three mouse tumor tissues and the most representative images were shown

Back to article page